Valuation Metrics Signal Enhanced Price Attractiveness
Suraksha Diagnostic Ltd’s price-to-earnings (P/E) ratio currently stands at 44.48, a figure that, while elevated in absolute terms, is considered very attractive relative to its historical valuation and peer group. This marks a notable improvement from previous assessments where the valuation was deemed merely fair. The price-to-book value (P/BV) ratio is 6.50, reflecting a premium but consistent with the company’s growth prospects and return metrics.
When compared to peers such as KMC Speciality (P/E 40.68, rated expensive) and Gujarat Kidney (P/E 77.85, very expensive), Suraksha Diagnostic’s valuation appears more reasonable. Even though the P/E remains higher than some attractive peers like GPT Healthcare (P/E 26.06) and Asarfi Hospital (P/E 25.85), the overall valuation grade upgrade to very attractive underscores a positive reassessment by market analysts.
Enterprise Value Multiples and Profitability Ratios
The enterprise value to EBITDA (EV/EBITDA) ratio for Suraksha Diagnostic is 16.62, which is lower than several peers such as Gujarat Kidney (44.73) and KMC Speciality (22.98), indicating a relatively better valuation on an operational earnings basis. The EV to EBIT ratio is 28.83, while EV to capital employed stands at 4.86, both suggesting efficient capital utilisation and operational leverage.
Return on capital employed (ROCE) is a healthy 15.47%, and return on equity (ROE) is 13.15%, reflecting solid profitability and effective management of shareholder funds. These returns support the premium valuation and justify the recent upgrade in the company’s mojo grade from Hold to Buy, with a mojo score of 74.0 as of 20 August 2026.
Stock Price Performance and Market Context
Suraksha Diagnostic’s current market price is ₹304.90, down 2.10% on the day, with a 52-week high of ₹333.65 and a low of ₹224.10. Despite the recent dip, the stock has outperformed the Sensex over the past month and year-to-date periods, delivering returns of 18.38% and 13.68% respectively, compared to the Sensex’s negative returns of -0.22% and -9.02% over the same intervals. This relative outperformance highlights investor confidence in the company’s growth trajectory and valuation appeal.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Peer Comparison Highlights Valuation Edge
Within the healthcare services sector, Suraksha Diagnostic’s valuation stands out as very attractive when benchmarked against a diverse peer set. For instance, Gaudium IVF and Lotus Eye Hospital trade at significantly higher P/E multiples of 35.78 and an extraordinary 1513.58 respectively, with corresponding EV/EBITDA ratios of 22.38 and 52.30. These elevated multiples reflect either niche market positioning or speculative premium, contrasting with Suraksha’s more balanced valuation.
Other peers such as Hemant Surgical and Hannah Joseph maintain attractive valuations with P/E ratios of 27.81 and 22.60, but Suraksha’s combination of a strong mojo score and upgraded valuation grade suggests it is well-positioned to capture market share and deliver shareholder value.
Quality and Growth Prospects Underpin Upgraded Rating
The company’s mojo grade upgrade from Hold to Buy on 20 August 2026 reflects improved confidence in its fundamentals and valuation. The mojo score of 74.0 places Suraksha Diagnostic comfortably in the Buy category, signalling robust quality metrics and growth potential. This upgrade is supported by consistent profitability, efficient capital deployment, and a valuation that has become more compelling relative to historical levels and sector peers.
While the PEG ratio remains elevated at 23.99, this metric should be interpreted cautiously given the company’s growth phase and sector dynamics. The absence of a dividend yield indicates reinvestment of earnings into expansion and capacity building, which may translate into stronger future earnings growth.
Want to dive deeper on Suraksha Diagnostic Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Investment Considerations and Outlook
Investors evaluating Suraksha Diagnostic Ltd should weigh the company’s improved valuation attractiveness against sector volatility and micro-cap risks. The healthcare services industry continues to benefit from rising demand for diagnostic and specialised medical services, driven by demographic trends and increasing health awareness.
Suraksha’s valuation upgrade to very attractive, combined with a mojo grade Buy, suggests that the stock is favourably positioned for medium to long-term appreciation. However, the relatively high P/E and PEG ratios indicate that expectations for growth are already priced in to some extent, necessitating close monitoring of earnings delivery and sector developments.
Comparatively, the stock’s recent price correction of 2.10% on 21 August 2026 may offer a tactical entry point for investors seeking exposure to a fundamentally sound healthcare services company with improving valuation metrics.
Summary
Suraksha Diagnostic Ltd’s transition from a fair to a very attractive valuation grade marks a pivotal moment for the stock within the healthcare services sector. Supported by strong profitability ratios, a mojo grade upgrade to Buy, and favourable peer comparisons, the company presents a compelling investment case. While valuation multiples remain elevated, the improved price attractiveness and solid fundamentals provide a sound basis for investor interest in this micro-cap healthcare services player.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
